Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.
Valneva’s vision is to contribute to a world where no one dies or suffers from a vaccine-preventable disease.
Valneva’s commercial portfolio includes two vaccines for travelers:
+ IXIARO®/JESPECT®, indicated for the prevention of Japanese encephalitis; and
+ DUKORAL®, indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli.
Valneva invests proceeds from its commercial business in R&D. The Company’s clinical pipeline includes a unique vaccine candidate against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada, and the US.
44800 Saint Herblain